Background: Hospital readmission within 30 days of discharge (30-d readmission) is an undesirable outcome. Readmission of patients with diabetes is common and costly. Most of the studies that have examined readmission risk factors among diabetes patients did not include potentially important clinical data.
H ospital readmission is an undesirable outcome that may be preventable. Recently, increasing attention is being focused on readmission of patients with diabetes. Diabetes affects a substantial proportion of hospitalized patients and is associated with considerable costs. Patients with diagnosed diabetes account for > 8 million discharges/year in the United States, 25% of all discharges. 1 In 2012, total US hospital cost attributable to diabetes patients was $124 billion, with 30-day readmissions contributing at least $20 billion. 2, 3 The best estimates of 30-day readmission rates among those with diabetes are 16.0%-20.4%, [4] [5] [6] [7] [8] and readmission is 17% more likely among patients with diabetes compared with those without. 5 A thorough understanding of readmission risk factors is needed to identify high-risk individuals and reduce readmission rates. Most of the studies that have examined readmission risk factors among diabetes patients did not include potentially important clinical data such as laboratory values and medication use history. [3] [4] [5] [6] [7] 9, 10 In a prior study that did examine such factors, the development and validation of the Diabetes Early Readmission Risk Indicator (DERRI) was presented. 8 Because the DERRI was designed as a predictive tool for use at the point-of-care in hospitalized patients before discharge, neither postdischarge information nor a comorbidity index were included. Furthermore, the number of predictors retained in the model was limited to maximize ease-of-use. Lastly, the study sample was split into development and validation datasets. To provide a more comprehensive understanding of 30-day readmission risk factors based on predischarge and postdischarge data, the entire DERRI sample of hospitalized patients with diabetes was analyzed for associations of sociodemographic, clinical, and administrative variables with readmission.
In addition to the variables previously evaluated in the DERRI development study, the following 4 variables were examined based on published data suggesting association with readmission among diabetes patients: having a follow-up appointment within 30 days of discharge, hospital length of stay (LOS), Charlson comorbidity index, 11 and discharge status from the index hospitalization. 3 Lastly, year of index discharge was included in the model to adjust for potential changes in readmission rates during the study period.
METHODS

Study Sample
In this retrospective cohort study, electronic medical records of 17,284 patients with 44,203 hospital discharges between January 1, 2004 and December 1, 2012 from an urban academic medical center (Boston Medical Center, Boston, MA) were analyzed. Boston Medical Center is the largest safety net hospital and busiest emergency services center in New England, with~500 beds. Inclusion criteria were a diagnosis of diabetes defined by an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) code of 250.xx associated with hospital discharge or the presence of a diabetes-specific medication on the preadmission medication list. Exclusion criteria were patients younger than 18 years on the day of an index admission, discharge by transfer to another hospital, discharge from an obstetric service, inpatient death, outpatient death within 30 days of discharge, missing data, or lacking 30 days of follow-up after discharge. Readmission that occurred within 8 hours after an index discharge was considered false positive and merged with the discharge to avoid counting inhospital transfer as a readmission. During the study period, patients received usual care. There was no systematic diabetes-focused intervention for discharge procedures other than inpatient consultation of the diabetes management team as requested by the primary hospital providers. The Boston Medical Center and Temple University Institutional Review Boards approved the protocol.
Definition of Variables
A total of 48 variables were evaluated for association with all-cause hospital readmission within 30 days of index discharge (Supplemental Table, Supplemental Digital Content 1, http://links.lww.com/MLR/B580). This included variables previously evaluated to develop a predictive model of readmission. 8 In addition, the following 4 variables were examined based on literature review: having a follow-up appointment within 30 days of discharge, hospital LOS, Charlson comorbidity index, 11 and discharge status from the index hospitalization. 3 This version of the Charlson index is a measure of comorbidity burden associated with inpatient death based on a set of 17 specific conditions that does not include any of the conditions used as covariates in the present study. Because the Charlson index includes chronic lung disease, malignant neoplasm, and the macrovascular complications of diabetes, these 3 factors were not included in the multivariable analysis. Lastly, year of index discharge was included in the model to adjust for potential changes in readmission rates during the study period. Variables based on ICD-9-CM codes were defined as previously reported. 8 Data were collected during the course of routine clinical care in the electronic medical record.
Variables were based on information at the time of the index admission. In general, the first laboratory values available during the 24 hours before the time of admission were used. The serum albumin level closest to the time of admission was used, up to 30 days before or during the admission. Most extreme blood glucose level was based on capillary point-of-care or venous values during the entire hospitalization.
Statistical Analyses
Summaries of categorical variables included counts and percentages, while means and standard deviations or medians and interquartile ranges were used for continuous variables. Readmitted patients were compared with nonreadmitted patients by χ 2 tests for categorical variables and 2-sample t tests or Wilcoxon rank sum tests for continuous variables. Non-normally distributed continuous variables, that is, admission serum creatinine and LOS, were log transformed for modeling procedures.
Univariate analyses were performed for all variables to determine those associated with 30-day readmission. Variables associated with readmission at the P < 0.1 level in univariate analyses were selected for multivariable modelling. Multivariable logistic regression with generalized estimating equations and best subset selection was performed to determine the adjusted associations of the variables with all-cause 30-day readmission. 12, 13 The generalized estimating equation method accounts for clustering of repeated observations, in this case, multiple discharges per patient. Variables independently associated with 30-day readmission at the P < 0.05 level were retained in the multivariable model. Model performance was evaluated by the c-statistic to represent the area under the receiver operating characteristic curve, for which higher values represent better discrimination. 14 All analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC). A P-value < 0.05 was considered statistically significant.
RESULTS
A total of 9034 (20.4%) discharges of 44203 index discharges in the study were associated with 30-day readmission for any cause. The study cohort is well-distributed across age and sex (Table 1) . A majority of the discharges were among patients who were unmarried, educated at a high-school level or less, disabled, retired, or unemployed, insured by Medicare or Medicaid, overweight or obese, and lived within 5 miles of the hospital. This is an ethnically diverse sample, with 45.5% of discharges identified as black, 15.5% as Hispanic, and 32.8% as white. Preadmission diabetes therapy included sulfonylureas for 15.2%, metformin for 28.1%, insulin therapy for 37.5% of all discharges. No microvascular complications were present in nearly 70% of discharges. In contrast, a majority discharges were of patients with at least 1 macrovascular complication. Other common comorbidities were depression, hypertension, chronic obstructive pulmonary disease or asthma, cardiac dysrhythmias, and anemia. The median LOS was 3.6 days.
Univariate analysis identified numerous factors associated with the risk of 30-day readmission (Table 1) . Those not associated with 30-day readmission were a diagnosis of . In addition to a high comorbidity burden according to the Charlson comorbidity index, several comorbidities were independently associated with a significantly increased risk of readmission, specifically, schizophrenia or a mood disorder, gastroparesis, cardiac dysrhythmias, anemia, and fluid or electrolyte disorders. Compared with those discharged home, patients discharged against medical advice (AMA) had 60% greater odds of being readmitted (OR, 1.60; 95% CI, 1.32-1.94). Similarly, being discharged AMA in the year before the index admission was associated with a 27% increased odds of being readmitted (OR, 1.27; 95% CI, 1.03-1.58). Discharges with longer LOS were more likely to be followed by a readmission than discharges with shorter LOS (OR, 1.14; 95% CI, 1.09-1.19). The c-statistic was 0.82. Among the 30-day readmissions, the median time to readmission was 11 days (Fig. 1) .
DISCUSSION
In this retrospective cohort study of 44,203 discharges of patients with diabetes, 48 sociodemographic, clinical, and administrative variables were evaluated for associations with all-cause 30-day readmission. In multivariable analysis, numerous risk factors for 30-day readmission were identified. The strongest risk factors were as follows: lacking an outpatient visit after discharge, duration of hospital LOS, prior discharge within 90 days before the index admission, current or prior discharge AMA, employment status of disabled, retired, or unemployed, race/ethnicity, health insurance coverage, comorbidity burden, and abnormal admission laboratory values.
Model performance was very good based on a c-statistic of 0.82. 15 This is a considerable improvement over the c-statistic of the DERRI, which was 0.70 in the training sample and 0.69 in the internal validation sample. 8 The DERRI is a prediction tool designed for use in hospitalized patients before discharge. Therefore, it was based on information obtainable on the day of admission, was limited to as few predictors as possible, and did not include a comorbidity index. In contrast, the current study provides a more comprehensive analysis that describes both predischarge and postdischarge risk factors for 30-day readmission, as well as a comorbidity index to adjust for the burden of comorbid conditions. All the predictors contained in the DERRI were confirmed to be associated with readmission, independent of the numerous additional risk factors included in the model. Notably, variables based on postdischarge information, that is, outpatient follow-up, LOS, and discharge status, were highly associated with readmission risk. Our model compares favorably to the performance of other models of readmission risk. The range of c-statistic among models specifically developed in patients with diabetes is 0.64-0.82. 9, 10, [16] [17] [18] A recent systematic review of models that predict 28-or 30-day readmission of any patients reported a c-statistic range of 0.21-0.88, with only 5 studies reporting a c-statistic > 0.8. 19 Of particular interest is the finding that an extreme high or low blood glucose level is associated with 30-day readmission. This confirms and extends previous work that showed a secondary hospital diagnosis of hypoglycemia was associated with 30-day readmission. 20 To our knowledge, the only other study to examine inpatient glycemic control and readmission was in patients with diabetes hospitalized for heart failure. 21 Increasing mean blood glucose and increasing A1c was associated with readmission for heart failure 30-90 days after hospital discharge.
Previous evidence on an association of race/ethnicity with readmission risk among patients with diabetes is conflicting, with some studies showing that blacks and Hispanics are at increased risk compared with whites and others reporting no difference in risk. 5, 7, 9, 16, 17, [22] [23] [24] Our finding that blacks and Hispanics had lower odds of readmission compared with whites adds to the conflicting evidence base. Differences in study populations and the specific sets of covariates analyzed may account for the different findings across studies.
Admission serum sodium, creatinine, albumin, white blood cell count, and hematocrit were each independently associated with 30-day readmission, suggesting that admission laboratory values can provide important readmission risk information. Whether these tests function as markers of illness or are causally related to readmission remains unknown. Higher creatinine levels have been associated with readmission risk among patients hospitalized with heart failure. 25 Inpatient laboratory tests have also been included in a readmission risk prediction model developed in unselected hospitalized patients in Maine, but the specific tests were not reported. 26 We are unaware of other studies, most of which are based on administrative data, that provide as extensive an evaluation of the relationship of inpatient laboratory values with 30-day readmission among patients with diabetes. Another risk factor that has not been reported among diabetes patients is receiving a blood transfusion, which was associated with lower odds of readmission. As with the laboratory tests, it is uncertain whether blood transfusion causes readmissions or not.
The relationship between postdischarge outpatient follow-up and readmission among patients with diabetes has been uncertain, with prior studies reporting increased, decreased, or U-shaped risk. 10, 16, 24 We found that lack of an outpatient visit within 30 days was associated with a nearly 6-fold increased odds of readmission. This is consistent with a large study that reported more than half of Medicare patients who were initially hospitalized for a medical condition then readmitted within 30 days did not have outpatient follow-up before the readmission. 27 Absence of outpatient follow-up may reflect poor health literacy, socioeconomic barriers, and/or a poor state of health, all of which could contribute to readmission risk. 28 Investigating reasons why patients fail to have outpatient follow-up may identify potential leverage points for intervention. It is worth noting that poor health literacy and social determinants of health are relatively unmodifiable, which raises questions about the extent to which hospitals should be penalized for excess 30-day readmission rates.
We found that 50% of 30-day readmissions occurred within 11 days after discharge. To our knowledge, time to readmission among patients with diabetes has not been previously reported. A study of unselected hospitalized patients in Maine found that > 50% of patients readmitted within 30 days experienced readmission by 15 days postdischarge. 26 Whether or not there is a difference in the timing of readmission between patients with and without diabetes remains unknown. Interventions to reduce readmission risk should take this timing into account.
There are a few limitations of this study of patients at a single urban academic medical center. Results may not be generalizable to other populations. Data on potential readmission risk factors such as hemoglobin A1c, diabetes type or duration, admitting service, and medications recommended upon discharge were not available. Furthermore, inferences about causality based on these retrospective, observational data are limited. Lastly, readmissions at other hospitals were not captured. However, it is unlikely that a substantial proportion of patients were readmitted elsewhere given that the readmission rate in the study sample is on the higher end of the range for reported readmission rates of patients with diabetes. These limitations are balanced by a relatively large sample size and a well-characterized population that allowed for the evaluation of numerous sociodemographic, administrative, and clinical factors.
Whether identification of these risk factors can be translated into lower readmission risk for diabetes patients remains a key unanswered question. These findings may lead to 2 strategies for reducing readmission risk that hospitals could consider to reduce their exposure to financial penalties. One is improving currently available readmission risk prediction tools to identify higher risk patients for intervention. It is clear that adding risk factors to the DERRI would improve its predictive accuracy. Increasing the number of factors, however, would increase the burden on users to collect and enter the additional data. Tools based on more comprehensive models than the DERRI may require integration in electronic health record systems to be useable and practical at the point-of-care for individual patients. A potentially automatable claim-based algorithm to predict allcause 30-day readmission among patients with type 2 diabetes has been reported, 9 however, based on our findings, it is likely that adding clinical data would improve predictive accuracy.
The second way our findings may be translated into reducing readmission risk is by considering the risk factors that are both modifiable and plausible as causal agents. For example, statin therapy was associated with lower readmission risk, and perhaps this could be a consideration in favor of initiating a statin upon discharge. There is substantial opportunity for improving adherence to guidelines with regard to statin therapy, as 1 study found that nearly half of patients with diabetes and 35% of patients with diabetes and a history of cardiovascular disease do not take a statin. 29 Higher hematocrit levels and blood transfusion were associated with lower readmission risk, whereas a diagnosis of anemia was associated with higher risk. It is possible that managing anemia may confer protection against readmission, which could become a factor in favor of performing blood transfusion among patients who have borderline indications. Likewise, high or low blood glucose levels were associated with higher risk of readmission, and optimizing glycemic control may protect against readmission risk. Hospital discharge is an often missed opportunity to adjust diabetes therapy, and these data suggest another reason why diabetes therapy should be optimized at discharge. 30 Given that lack of outpatient follow-up within 30 days was a very strong risk factor for readmission, it is plausible that receiving outpatient follow-up may reduce readmission risk. Patients with diabetes could be prioritized to receive outpatient follow-up within 10 days, based on the median time to readmission of 11 days. Improving outpatient follow-up is particularly attractive as an intervention for hospitals because it is more of a systemsbased practice issue than the other more individual-level care issues discussed above. One small study of 100 indigent patients with diabetes suggests that postdischarge follow-up within 5 days of discharge may reduce readmission risk. 31 Additional research, ideally adequately-powered randomized controlled trials, would be required to test these hypotheses.
In conclusion, this relatively large retrospective cohort study of patients with diabetes identified numerous risk factors for all-cause 30-day readmission in a model with very good discrimination. A number of previously reported risk factors were confirmed, and several novel risk factors were identified, including inpatient blood transfusion, admission albumin and white blood cell count, and use of statins and glucocorticoids. Postdischarge factors add to the predictive accuracy achieved by predischarge factors. Hospital readmission among patients with diabetes poses a large burden on health care systems and is associated with great personal and financial costs. A better understanding of readmission risk may ultimately lead to lowering that risk by improving interventions to reduce readmission risk as well as targeting of interventions to high-risk patients.
